肾细胞癌的立体定向体部放射治疗策略及进展

Strategy and progress of stereotactic body radiotherapy for renal cell carcinoma

肾细胞癌(RCC)是泌尿生殖系统中侵袭性最高的恶性肿瘤之一,预后不佳,尤其是发生RCC转移的患者。传统观点一般认为肾细胞癌对放疗不敏感。立体定向体部放射治疗(SBRT)与常规放疗相比,具有高精准度、较高照射剂量、对周围组织损伤小等特点。近年来,SBRT在原发性及转移性RCC治疗中均展现了确切的疗效。SBRT联合靶向治疗以及免疫治疗等联合方案可以提高原发和晚期转移RCC患者的肿瘤局部控制率,且不良反应较小。本文就SBRT联合靶向治疗以及免疫治疗的策略和进展等方面进行综述。

Renal cell carcinoma(RCC)is one of the most aggressive malignancies in the genitourinary system with a poor prognosis,especially in patients with RCC who have metastases.RCC is conventionally considered not sensitive to radiotherapy.Compared with conventional radiotherapy,stereotactic body radiotherapy(SBRT)has the characteristics of higher precision,higher irradiation dose,and less damage to the surrounding tissue.In recent years,SBRT has shown definite efficacy in the treatment of primary and advanced metastatic RCC.SBRT combined with targeted therapy and immunotherapy can improve the local tumor control rate and cause fewer adverse reactions in patients with primary and advanced metastatic RCC.This article reviews the literature on the strategy and progress of SBRT in combination with targeted therapy and immunotherapy.